Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Teva Investigational Site 14683, Pittsburgh

Teva Investigational Site 14713, Richmond

Teva Investigational Site 14692, Winston-Salem

Teva Investigational Site 14722, Greensboro

Teva Investigational Site 14696, Gastonia

Teva Investigational Site 14710, Charlotte

Teva Investigational Site 14715, Spartanburg

Teva Investigational Site 14718, Spartanburg

Teva Investigational Site 14719, Gaffney

Teva Investigational Site 14707, Union

Teva Investigational Site 14681, Charleston

Teva Investigational Site 14695, Mt. Pleasant

Teva Investigational Site 14691, Greenville

Teva Investigational Site 14686, Easley

Teva Investigational Site 14711, Daytona Beach

Teva Investigational Site 14694, Edgewater

Teva Investigational Site 14699, DeLand

Teva Investigational Site 14688, Orlando

Teva Investigational Site 14701, Miami

Teva Investigational Site 14689, Miami

Teva Investigational Site 14678, Miami

Teva Investigational Site 14725, Brandon

Teva Investigational Site 14704, Anniston

Teva Investigational Site 14682, Andalusia

Teva Investigational Site 14712, Mobile

Teva Investigational Site 14680, Grove City

Teva Investigational Site 14708, Columbus

Teva Investigational Site 14709, Toledo

Teva Investigational Site 14724, Willoughby

Teva Investigational Site 14703, Dayton

Teva Investigational Site 14679, Valparaiso

Teva Investigational Site 14705, Chesterfield

Teva Investigational Site 14717, Omaha

Teva Investigational Site 14716, San Antonio

Teva Investigational Site 14702, Peoria

Teva Investigational Site 14706, Gold River

Teva Investigational Site 14687, Spokane

Teva Investigational Site 14720, Waterbury

Teva Investigational Site 14677, North Dartmouth

Teva Investigational Site 14684, Toms River